Search:
This item requires a subscription.
Funding for cancer drugs – time for clearer thinking BJCM, Volume 2, Number 2.
Welcome to issue 2.2. As we prepare to bring you the next issue of the journal, controversy and confusion reign about trastuzumab (Herceptin®, Roche, UK) and the treatment of early-stage human epidermal growth factor receptor 2 (HER2) positive breast cancer.
To view this item, select one of the options below:
Purchase access
Sign in
email address
Password
Important
All the articles are in PDF format.
To view the articles you will need Adobe Acrobat Reader.
To download a copy, free of charge, please click here.